Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 14/20 | 0.79 |
| ▸ | SRC | P12931 | 7/20 | 0.79 |
| ▸ | PKMYT1 | Q99640 | 3/20 | 0.79 |
| ▸ | BCR | P11274 | 3/20 | 0.79 |
| ▸ | EPHB6 | O15197 | 2/20 | 0.79 |
| ▸ | EGFR | P00533 | 2/20 | 0.79 |
| ▸ | LCK | P06239 | 2/20 | 0.79 |
| ▸ | FYN | P06241 | 2/20 | 0.79 |
| ▸ | CSF1R | P07333 | 2/20 | 0.79 |
| ▸ | YES1 | P07947 | 2/20 | 0.79 |
| ▸ | LYN | P07948 | 2/20 | 0.79 |
| ▸ | RET | P07949 | 2/20 | 0.79 |
| ▸ | HCK | P08631 | 2/20 | 0.79 |
| ▸ | KIT | P10721 | 2/20 | 0.79 |
| ▸ | BRAF | P15056 | 2/20 | 0.79 |
| ▸ | EPHA1 | P21709 | 2/20 | 0.79 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.79 |
| ▸ | EPHA3 | P29320 | 2/20 | 0.79 |
| ▸ | EPHA8 | P29322 | 2/20 | 0.79 |
| ▸ | EPHB2 | P29323 | 2/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31634939 | 0.95 | ABL1 (0.86) | ABL1SRCPKMYT1BCREPHB6 | |
| SCHEMBL20537131 | 0.95 | ABL1 (0.86) | ABL1SRCPKMYT1BCREPHB6 | |
| SCHEMBL20536999 | 0.95 | ABL1 (0.78) | ABL1SRCPKMYT1BCREPHB6 | |
| SCHEMBL31634940 | 0.95 | ABL1 (0.78) | ABL1SRCPKMYT1BCREPHB6 | |
| SCHEMBL13378598 | 0.92 | ABL1 (0.89) | ABL1SRCPKMYT1BCREPHB6 | |
| SCHEMBL31634945 | 0.92 | ABL1 (0.89) | ABL1SRCPKMYT1BCREPHB6 | |
| SCHEMBL22964741 | 0.90 | ABL1 (0.84) | ABL1SRCPKMYT1BCREPHB6 | |
| SCHEMBL1704876 | 0.90 | ABL1 (0.92) | ABL1SRCPKMYT1BCREPHB6 | |
| SCHEMBL28519145 | 0.89 | SIK2 (0.85) | ABL1SRCPKMYT1BCREPHB6 | |
| SCHEMBL28426331 | 0.89 | ABL1 (0.84) | ABL1SRCPKMYT1BCREPHB6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250340886-A1 | INTRACELLULAR KINASE ASSOCIATED WITH RESISTANCE AGAINST ANTI-TUMOUR IMMUNE RESPONSES, AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2025-11-06 | — | — | US | disclosed |
| US-12338440-B2 | Intracellular kinase associated with resistance against anti-tumour immune responses, and uses thereof | IOMX THERAPEUTICS AG (DE) | 2025-06-24 | — | — | US | disclosed |
| US-20210040486-A1 | INTRACELLULAR KINASE ASSOCIATED WITH RESISTANCE AGAINST ANTI-TUMOUR IMMUNE RESPONSES, AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2021-02-11 | — | — | US | disclosed |
| EP-3391907-A1 | INTRACELLULAR KINASE SIK3 ASSOCIATED WITH RESISTANCE AGAINST ANTI-TUMOUR IMMUNE RESPONSES, AND USES THEREOF | iOmx Therapeutics AG (DE) | 2018-10-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210040486-A1 | INTRACELLULAR KINASE ASSOCIATED WITH RESISTANCE AGAINST ANTI-TUMOUR IMMUNE RESPONSES, AND USES THEREOF | SIK3, SIK1, SIK2 | ABL1 1088/4885SRC 859/4885PKMYT1 2522/4885 |
| US-20250340886-A1 | INTRACELLULAR KINASE ASSOCIATED WITH RESISTANCE AGAINST ANTI-TUMOUR IMMUNE RESPONSES, AND USES THEREOF | SIK3, SIK1, SIK2 | ABL1 1088/4885SRC 859/4885PKMYT1 2522/4885 |
| US-12338440-B2 | Intracellular kinase associated with resistance against anti-tumour immune responses, and uses thereof | SIK3, SIK1, SIK2 | ABL1 1088/4885SRC 859/4885PKMYT1 2522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.